Oncology
2 drugs are in development for Biliary Tract Cancer.
- Companies
- 2
- Clinical trials
- 26
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Biliary Tract Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| tovecimig | Compass Therapeutics, Inc. (CMPX) |
Phase 1(1)
| Drug | Company |
|---|---|
| lncb74 | NextCure, Inc. (NXTC) |
About this indication
Biliary Tract Cancer context
Oncology·MeSH: Biliary Tract Neoplasms (D001661)
Narrower concept of MeSH descriptor Biliary Tract Neoplasms
Prevalence
4.2 / 100K
Incidence
3.0 / 100K/yr
Compare drugs
Frequently asked questions
How many drugs are in development for Biliary Tract Cancer?
BioSniper tracks 2 drugs in development for Biliary Tract Cancer across 2 companies.
How many clinical trials target Biliary Tract Cancer?
There are 26 clinical trials targeting Biliary Tract Cancer tracked by BioSniper.
What is the prevalence of Biliary Tract Cancer?
The estimated prevalence of Biliary Tract Cancer is approximately 4.2 per 100,000 population.